Maxcyte Share Discussion Threads

[assagai] 02/11/2020 07:41

AGM results? Discussions?
Surely a requirement of AIM?

[gsbmba99] 22/10/2020 11:06

CRISPR did a webinar on the trial and a presentation. Not a medical person so just trying to understand some of the technical commentary. According to the presentation, the patient who died was a "72-year-old male with relapsed transformed follicular lymphoma following five prior lines of therapy, including autologous stem cell transplant". This patient was the only patient in dose level 4 (DL4) being the highest dosage in the trial. The patient experienced Grade 2 CRS (cytokine release syndrome) at day 5 but this resolved. On day 25, patient was assessed to be a complete responder (ie in complete remission). On day 26, admitted with febrile neutropenia (abnormally low level of neutrophils, a type of white blood cell, accompanied by fever). Confusion and memory loss started at day 28 and further deterioration required intubation (induced coma). Patient initially treated for ICANS (immune effector cell-associated neurotoxicity syndrome) and subsequently determined to have reactivation of HHV-6 (human herpes virus 6) and HHV-6 encephalitis (inflammation of the brain). Patient died at day 52 after family requested withdrawal of care. Seems like the drug worked but that a reactivated viral infection was unable to be overcome. In any event, CRISPR is still enrolling in this trial (and others).

[nimbo1] 21/10/2020 22:15

If I’m reading everything right...for the patient cohort in this particular trial it seems they are very ill individuals suffering from cancer which has been unable to be treated by other methods... therefore likely deaths will occur during cancer trial periods at some point because of how ill patients are (unfortunately for them).

The barons article is v positive

[rgmgo] 21/10/2020 14:54

Sad news out on a trial from CRISPR Therapeutics

MXCT is clearly insulated from the economic effect of any particular programme due to its diverse royalty pipeline. Further details will presumably emerge on the precise circustances and whether there are any broader implications.

[the stigologist] 18/10/2020 09:19

Video explaining Crispr for AIM investors

#HZD #MXCT #C4XD

[nimbo1] 14/10/2020 16:33

Yes because they’ve publicly announced it is on track to happen this year just recently.

[assagai] 13/10/2020 22:31

Hi nimbo, do you really think Carma spin off will happen this year? Have I missed something?

[nimbo1] 13/10/2020 21:24

Yep. Should be Carma spin off this Year and Nasdaq listing in 2021.

[assagai] 13/10/2020 08:33

Building their team for NASDAQ?

[nimbo1] 09/10/2020 12:57

glad it worked out ok.

I think my first buy here was 1.10 or something, which I promptly sold when I got nervous. Fortunately started buying back at 1.20 - 2.50... its a 10% position for me now.

I would add another 50% to my holding on any significant drop...because I believe this can be a 1bil + company and as Adam said a few posts ago very rare to have the chance of spotting them early doors...

GL to us all!

[junior21] 09/10/2020 12:31

Nimbo, a belated thanks for mentioning this on the SHA thread a few months back. My £500 initial investment spreadbet has returned over 5 times that in profit. I've also got a few in my SIPP. Thanks again.

[acuere] 09/10/2020 10:10

Nimbo, I’m sure they’ll have no trouble passing any excess onto to another fund. Tho they may be better off just changing their maximum holding limit.

[davep4] 09/10/2020 01:03

davegk
From memory if the NASDAQ listing doesn’t happen there is also a 10% kicker.

[nimbo1] 08/10/2020 13:20

some funds will be breaching maximum percentage position size!

[multibagger] 08/10/2020 12:09

Looks like there is big seller about as Offer not moving despite a lot of buys ?

Happy to hold :)

[davegk] 08/10/2020 10:32

Found the answer
The Company currently has two lines of Common Stock admitted to trading on AIM: an unrestricted line of Common Stock trading under the symbol MXCT and a new restricted line of Common Stock under the symbol MXCL which is restricted under Regulation S Category 3 such that purchasers cannot sell or otherwise transfer such Common Stock except pursuant to the requirements of Regulation S until at least the expiry of one year after the closing of the offering which closed on 22 May 2020. There are no other restrictions on the transfer of AIM securities.

[davegk] 08/10/2020 10:30

Why the two epic's MXCT & MXCL ?

[nimbo1] 08/10/2020 07:56

crispr pioneers winning Nobel prize in chemistry - maxcyte an important part of bringing crispr towards commercial reality with companies like crispr and editas etc.

[homebrewruss] 07/10/2020 14:00

This link to the Telegraph article should be accessible:

[adamb1978] 07/10/2020 11:53

I wouldn't sell for anything close to 500p per share! They're a picks and shovels company and if they can maintain a 20%-30% growth rate from continually increasing their installed base, they could be worth 10x the current share price in 5-10 years' time!!

[edwardt] 07/10/2020 11:41

he has owned it for a long time btw.

[edwardt] 07/10/2020 11:41

the penny has finally dropped as they say.

[acuere] 07/10/2020 11:18

It’s quite a good write up from Questor.
It comes after speaking to Richard Penny who runs the Crux UK Special Situations Fund. He currently values the shares at 500p but anticipates they would be valued much higher if, as he anticipates, they move to a Nasdaq listing next year.